MedPath

Effect of the GLP-1 analogue liraglutide on intragastric pressure and satiation during nutrient drink infusion.

Phase 1
Conditions
healthy volunteersno medical condition
drugs will be studied because they are known to influence gastric motility.
Registration Number
EUCTR2010-023226-20-BE
Lead Sponsor
KULeuven
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
0
Inclusion Criteria

Healthy volunteers (18-45 years) who have no bowel symptoms and who are in good general health are eligible
for the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• They have relevant underlying disease (cardia, pulmonary, metabolic, kidney or liver disease, …)
• They have a history of esophageal or gastric surgery, or recurrent or intermittent upper gastrointestinal
symptoms (upper abdominal pain, nausea, vomiting, bothersome fullness or early satiation, heartburn,
regurgitation,…)
• They have a history of allergy to several types of drugs or food.
• They have ever been treated for depression
• There is a possibility of becoming pregnant during the study period.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: We set out to investigate the effect of liraglutide on the relation between gastric accommodation and satiation by measuring the IGP during intragastric nutrient drink infusion.;Secondary Objective: /;Primary end point(s): liquid nutrient tolerance to reach maximum satiation
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath